Gemcitabine–docetaxel instead of BCG: 80% free of high-grade recurrence at three years in a small trial

Design

Single-arm, open-label phase 2 trial

Population

25 patients with BCG-naive high-risk non-muscle-invasive bladder cancer

Primary outcome

High-grade recurrence-free survival at 24 and 36 months (secondary endpoints)

Effect

84% at 24 months (63% to 94%); 80% at 36 months (58% to 91%)

A single-arm, open-label phase 2 trial gave intravesical gemcitabine followed by docetaxel — weekly for six weeks, then monthly for two years — to 25 patients with BCG-naive high-risk non-muscle-invasive bladder cancer; 64% had high-grade T1 disease and 36% carcinoma in situ.

With a median follow-up of 50 months, high-grade recurrence-free survival was 84% at 24 months (95% CI 63% to 94%) and 80% at 36 months (58% to 91%). No patient progressed while on treatment, and two (8%) eventually had cystectomy. Grade 3 adverse events — mainly haematuria and urinary infection — occurred in 20%.

With 25 patients and no comparison arm, this cannot show equivalence with BCG, which remains the standard first-line treatment. It matters wherever BCG supply is unreliable, as it has been in many countries.

• Keep BCG as first-line intravesical treatment for high-risk non-muscle-invasive bladder cancer where it is available.
• Consider gemcitabine–docetaxel when BCG is unavailable, ideally within a protocol or trial.
• Counsel patients that this option rests on small single-arm data without a direct comparison to BCG.
• Continue standard cystoscopic surveillance whichever agent is used.

Why it matters

BCG shortages have repeatedly forced urologists to choose alternatives with limited evidence.

Don't overread it

Twenty-five patients in a single-arm phase 2 trial; this does not establish non-inferiority to BCG.

The statistics, in plain English

With 25 patients, each recurrence moves the estimate by 4 percentage points, which is why the interval runs from 58% to 91%. Without a control arm, the result cannot be compared directly with BCG.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.